Journal
MOLECULES
Volume 26, Issue 21, Pages -Publisher
MDPI
DOI: 10.3390/molecules26216482
Keywords
breast cancer; HER2; radionuclide molecular probes; molecular imaging; clinical trials
Funding
- National Natural Science Foundation of China [81601522]
- Medical Youth Talent Project of Jiangsu Province [QNRC2016749]
- Gusu Health Talent Program [GSWS2020013]
- Suzhou People's Livelihood Science and Technology Project [SYS2019038]
- Project of State Key Laboratory of Radiation Medicine and Protection, Soochow University [GZK1202127]
- open Foundation of Nuclear Medicine Laboratory of Mianyang Central Hospital [2021HYX023, 2021HYX026, 2021HYX029]
Ask authors/readers for more resources
Breast cancer is the most frequently occurring cancer globally, with HER2 overexpression affecting prognosis. Molecular imaging technologies can non-invasively, in real time, and quantitatively reflect the expression status of HER2 in tumors, providing a new approach for treatment selection and monitoring treatment response for patients.
As the most frequently occurring cancer worldwide, breast cancer (BC) is the leading cause of cancer-related death in women. The overexpression of HER2 (human epidermal growth factor receptor 2) is found in about 15% of BC patients, and it is often associated with a poor prognosis due to the effect on cell proliferation, migration, invasion, and survival. As a result of the heterogeneity of BC, molecular imaging with HER2 probes can non-invasively, in real time, and quantitatively reflect the expression status of HER2 in tumors. This will provide a new approach for patients to choose treatment options and monitor treatment response. Furthermore, radionuclide molecular imaging has the potential of repetitive measurements, and it can help solve the problem of heterogeneous expression and conversion of HER2 status during disease progression or treatment. Different imaging probes of targeting proteins, such as monoclonal antibodies, antibody fragments, nanobodies, and affibodies, are currently in preclinical and clinical development. Moreover, in recent years, HER2-specific peptides have been widely developed for molecular imaging techniques for HER2-positive cancers. This article summarized different types of molecular probes targeting HER2 used in current clinical applications and the developmental trend of some HER2-specific peptides.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available